Cell Lines

California Stem Cell has developed a repository of several hESC lines for use in therapeutics for multiple chronic diseases as well as a tool for innovative research technologies.

CSC's hESC lines are derived from a morula stage embryos, by removing the zona pellucida and expanding the embryonic pluripotent stem cells without the use of feeder layers, which makes our hESC lines suitable for clinical and therapeutic use. California Stem Cell hESC lines express all the markers of pluripotency, have ability to differentiate into all three lineages and do not carry any genetic abnormalities.

CSC's hESC lines are created according to Good Tissue Practice (GTP) regulations and quality control, and have been Federally registered. As a result, our hESC lines are FDA-compliant and clinically relevant.

CSC has employed a freezing protocol that has resulted in the banking of extremely large numbers of early passage cells. This protocol ensures that each hESC line will be available for decades in numbers sufficient to sell pre-clinical and clinically enabling quantities to multiple parties, run several clinical trials, and generate decades worth of income from product sale.

CSC's hESC lines have been fully characterized for differentiation potential and 'stemness'. Our characterization protocols exceed academic and industry standards, and conclusively demonstrate that the lines are pluripotent and capable of differentiating into all of our high purity human cell populations.

CSC's hESC lines have several advantages over other hESC lines including derivation and maintenance in fully defined conditions, historical profiling, availability at very low passage numbers for virtually indefinite expansion capability, and clinical compliance. In brief, our hESC lines were bred specifically for the clinic using standards that meet FDA requirements.